Content overview: “Merck and Kelun-Biotech ADC Drug Reduces Death Risk by One-Third in Advanced Endometrial C”. An experimental antibody-drug conjugate (ADC) from Merck and China’s Kelun-Biotech has achieved a significant milestone in advanced endometrial cancer. In a Phase 3 trial, the therapy reduced the risk of death by one-third compared to standard treatment, underscoring its potential as a new option fo In a Phase 3 trial, the therapy reduced the risk of death by one-third compared to standard treatment, underscoring its potential as a new option for patients with limited alternatives.
The drug targets a specific protein on cancer cells, delivering a potent cytotoxic payload directly to tumors. The results mark a major advance for endometrial cancer, which has seen few breakthroughs in recent years. Advanced or recurrent disease carries a poor prognosis, and current treatments often provide only modest benefit. This listing links straight to the original page, where the content is available in full.